Study summary

Semaglutide lowered the risk of kidney failure and death by 24%

FLOW trial (semaglutide and kidneys) · 3,533 people, phase 3 · Published July 2024, New England Journal of Medicine

24%lower risk of major kidney events

What was tested

Weekly semaglutide 1.0 mg against placebo in people with type 2 diabetes and chronic kidney disease.

What they found

What it means

Added GLP-1 drugs to SGLT2 inhibitors and finerenone as kidney-protecting treatments in diabetes.

N Engl J Med, via PubMed ↗ Trial record NCT03819153 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.